| Literature DB >> 26137100 |
Takuma Nomiya1, Hiroko Akamatsu2, Mayumi Harada1, Ibuki Ota2, Yasuhito Hagiwara2, Mayumi Ichikawa2, Misako Miwa2, Masaomi Mizutani3, Tomoyuki Kato4, Akira Nagaoka4, Yoshihiko Tomita4, Kenji Nemoto2.
Abstract
The current study reports the case of a large retroperitoneal tumor treated with modified simultaneous integrated boost (SIB) radiotherapy. A 45-year-old female presented to the emergency department complaining of left abdominal pain and fever. A computed tomography scan detected a retroperitoneal tumor of 12×16×16 cm, and a biopsy revealed a poorly-differentiated adenocarcinoma. The patient was diagnosed with a large adenocarcinoma originating from the left ureter, with no distant metastasis. Due to the patient's poor physical condition, surgery was not recommended, and the patient was referred to the Department of Radiation Oncology (Yamagata University Hospital, Yamagata, Japan). Modified SIB radiotherapy was administered following the acquisition of written consent from the patient. The total irradiation dose to the center of the tumor and to the surrounding healthy tissue was ∼96 Gy/33 fractions and <60 Gy/33 fractions, respectively. At the end of the radiotherapeutic course, the tumor volume was reduced by ≥80%, and the residual tumor was surgically resected. As a result of the resection, a complete pathological response was confirmed; the patient has been recurrence-free for >3 years with no complications. Modified SIB radiotherapy may be safely administered, with favorable outcomes. Complete recovery can be achieved with this technique, even in a patient with a large radioresistant tumor.Entities:
Keywords: clinical trial; radiotherapy; retroperitoneal neoplasm; technique
Year: 2015 PMID: 26137100 PMCID: PMC4473302 DOI: 10.3892/ol.2015.3095
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967